7th Sep 2007 14:20
Hikma Pharmaceuticals Plc07 September 2007 Notification of transaction by a Director LONDON, 7 September 2006 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the transfer of his entire directholding of 632,000 ordinary shares of 10 pence each in the capital of theCompany, to HMS Holding SAL, a company 99.66 percent owned by him. The remainingoutstanding shares of HMS Holding SAL are held equally between Mr. Darwazah'swife, and his son, Mazen Darwazah. The transfer was made for nil considerationand was made on 6 September 2006. The shares transferred represent 0.374 per cent. of the issued ordinary sharesof 10 pence each in the capital of the Company, and following the notificationMr. Darwazah no longer has a direct holding in the Company's ordinary shares. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relatesboth to DR 3.1.4R(1)(a) and section 324 (as extended by section 328) of theCompanies Act 1985. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company SecretarySusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About HikmaHikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals